Table 1.
Potential financial burden of CM patients at different disease stages from diagnosis up to 3 years of follow up under the SUS perspective
| Stage | Outpatient visit office | Laboratory exam | Imaging exam | Surgery/ pathological analysis | Cancer Drugs | TOTAL | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (SUS) | (R$a) | % | (R$) | % | (R$) | % | (R$) | % | (R$) | % | (R$) |
| 0 | 75 | 21% | 0 | 0% | 0 | 0% | 283 | 79% | 0 | 0% | 359 ± 35 |
| IA | 116 | 1.9% | 158 | 2.5% | 2574 | 41.4% | 3269 | 52.6% | 99 | 1.6% | 6218 ± 621 |
| IB | 119 | 1.5% | 179 | 3% | 3043 | 37.7% | 4245 | 52.5% | 432 | 5.4% | 8022 ± 802 |
| II | 129 | 1.4% | 257 | 2.7% | 3147 | 33.6% | 4245 | 45.4% | 1,6 | 16.9% | 9365 ± 936 |
| rIII | 134 | 1.1% | 583 | 4.7% | 3145 | 25.6% | 2861 | 23.3% | 5,6 | 45.3% | 12,285 ± 1228 |
| unIII+IV | 85 | 1.1% | 419 | 5.2% | 6865 | 85.1% | 701 | 8.6% | 0 | 0% | 8070 ± 807 |
aBrazilian currency: Reais (R$), R$1,0 = USD0,191,898;
Costs estimated by the SIGTAP table according to medical procedures most commonly applied